(“Bioventix” or “the Company”)
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 26 April 2022 that on 25 April 2022 Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 3 ordinary shares of 5 pence each in the Company (“Ordinary Shares”), at an average price of 3,500 pence per Ordinary Share (the “Purchase”). The shares were purchased under a dividend reinvestment plan (DRIP).
Following the Purchase, Bruce Hiscock has a beneficial interest in 424 Ordinary Shares, representing approximately 0.01 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
Chief Executive Officer
|Tel: 01252 728 001|
Geoff Nash/Simon Hicks
|Tel: 020 7220 0500|
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (“MAR”), and is disclosed in accordance with the company’s obligations under Article 17 of MAR.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|1||Details of the person discharging managerial responsibilities / person closely associated|
|2.||Reason for the Notification|
|a)||Position/status||Chief Financial Officer|
|b)||Initial notification/Amendment||Initial notification|
|3.||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|4.||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the Financial instrument, type of instrument||Ordinary Shares of 5 pence each|
|b)||Nature of the transaction||Purchase of Ordinary Shares|
|c)||Price(s) and volume(s)||3 Ordinary Shares|
· Aggregated volume
|Purchase of 3 Ordinary Shares at 3,500 pence each|
|e)||Date of the transaction||25 April 2022|
|f)||Place of the transaction||London Stock Exchange, AIM Market (XLON)|